Next-generation sequencing of TCR in CD8+ cells from biopsies of metastatic melanoma prior to treatment showed that a less diverse repertoire and thus a higher abundance of specific clones is accompanied by a better outcome of PD1 blockade therapy [49]. The gene discussed is CD8A; the disease is metastatic melanoma.